FMP
Medifast, Inc.
MED
NYSE
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
12.15 USD
-0.23 (-1.89%)
Latest MED News
zacks.com
2 days ago
Medifast Trades Near 52-Week Low: What's the Best Move Now?
MED faces steep revenue declines and coach losses but aims to rebound through innovation, marketing and new GLP-1-focused initiatives.
seekingalpha.com
Mar 28, 2025
Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect
Medifast, Inc.'s business is deteriorating as GLP-1 medication has lowered demand, causing a vicious flywheel effect as coaches are exiting the platform. The company is trying to reposition itself as a GLP-1 adjacent business, but the repositioning hasn't shown results so far with a deteriorating immediate earnings outlook. MED stock now trades below the company's net cash position, but due to high earnings uncertainty, the low valuation is justified.
zacks.com
Feb 19, 2025
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.
seekingalpha.com
Feb 18, 2025
Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call.
zacks.com
Feb 18, 2025
Medifast (MED) Q4 Earnings and Revenues Beat Estimates
Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago.
Danny Green
Feb 5, 2025
Medexus Pharmaceuticals' Financial Performance and Strategic Expansion
Medexus Pharmaceuticals, trading under the symbol MEDXF on the PNK exchange, is a specialty pharmaceutical company focused on the development and commercialization of innovative and rare disease treatments. The company competes with other pharmaceutical firms in the niche market of rare diseases. On February 5, 2025, Medexus reported earnings per share (EPS) of $0.03, surpassing the estimated $0.02, showcasing its ability to exceed market expectations. Despite the positive EPS, Medexus generate...
Tony Dante
Feb 5, 2025
Medexus Pharmaceuticals Quarterly Earnings Overview
Medexus Pharmaceuticals, trading under the symbols TSX: MDP and OTCQX: MEDXF, is a specialty pharmaceutical company. It focuses on the acquisition and distribution of innovative pharmaceutical products across North America. The company is set to release its quarterly earnings on February 5, 2025, with analysts estimating an earnings per share of $0.02 and projected revenue of $40.8 million. The company has scheduled a conference call for February 6, 2025, to discuss its financial results for th...
businesswire.com
Feb 4, 2025
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2024 on Tuesday, February 18, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chie.
zacks.com
Jan 22, 2025
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space.
zacks.com
Jan 8, 2025
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.
